​

BioNTech SE (BNTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

BNTX Stock Forecast

BioNTech SE (BNTX) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $118.67, with a high of $134.00 and a low of $110.00. This represents a 13.11% increase from the last price of $104.92.

$80 $91 $102 $113 $124 $135 High: $134 Avg: $118.67 Low: $110 Last Closed Price: $104.92

BNTX Stock Rating

BioNTech SE stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (82.61%), 4 Hold (17.39%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 23 4 19 0 Strong Sell Sell Hold Buy Strong Buy

BNTX Price Target Upside V Benchmarks

TypeNameUpside
StockBioNTech SE13.11%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts3416
Avg Price Target$118.67$125.25$122.06
Last Closing Price$104.92$104.92$104.92
Upside/Downside13.11%19.38%16.34%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 254145--23
May, 253135--21
Apr, 255134--22
Mar, 255125--22
Feb, 254125--21
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 02, 2025Daina GrayboschLeerink Partners$112.00$113.10-0.97%6.75%
May 29, 2025Asad HaiderGoldman Sachs$110.00$98.4511.73%4.84%
May 14, 2025Robert BurnsH.C. Wainwright$134.00$97.2737.76%27.72%
Apr 01, 2025H.C. Wainwright$145.00$90.2960.59%38.20%
Nov 19, 2024Cory KasimovEvercore ISI$125.00$80.8054.70%19.14%
Nov 13, 2024Daina GrayboschLeerink Partners$121.00$80.8049.75%15.33%
Nov 08, 2024Chris ShibutaniGoldman Sachs$137.00$110.6623.80%30.58%
Nov 04, 2024Etzer DaroutBMO Capital$126.00$108.9715.63%20.09%
Sep 23, 2024Terence FlynnMorgan Stanley$145.00$113.0528.26%38.20%
Sep 17, 2024Akash TewariJefferies$150.00$123.9721.00%42.97%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 29, 2025Goldman SachsBuyNeutralinitialise
May 14, 2025H.C. WainwrightBuyBuyhold
May 06, 2025CitigroupBuyBuyhold
Nov 19, 2024Evercore ISIOutperformupgrade
Nov 13, 2024Leerink PartnersOutperformOutperformhold
Nov 08, 2024Goldman SachsBuyBuyupgrade
Oct 21, 2024Cowen & Co.HoldHoldhold
Oct 21, 2024Cowen & Co.BuyBuyhold
Oct 07, 2024UBSBuyBuyhold
Sep 23, 2024Morgan StanleyEqual-WeightOverweightupgrade

Financial Forecast

EPS Forecast

$-10 $2 $14 $26 $38 $50 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.06$42.18$38.78------
Avg Forecast$-1.59$36.10$34.97$4.31$-3.16$-3.35$-3.47$-3.25$-2.46
High Forecast$-1.05$48.32$46.41$4.81$-1.30$-0.06$-0.33$0.74$-1.59
Low Forecast$-2.12$23.91$25.17$3.93$-4.51$-6.55$-8.43$-9.21$-3.52
Surprise %-103.77%16.84%10.90%------

Revenue Forecast

$0 $5B $10B $15B $20B $25B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$482.32M$18.98B$17.31B$3.82B-----
Avg Forecast$450.03M$19.46B$17.85B$4.62B$2.74B$2.67B$2.67B$2.88B$3.64B
High Forecast$567.18M$24.53B$22.33B$5.53B$2.84B$3.59B$2.77B$2.96B$4.86B
Low Forecast$333.12M$14.41B$14.00B$4.37B$2.57B$1.99B$2.58B$2.80B$2.65B
Surprise %7.18%-2.50%-3.00%-17.39%-----

Net Income Forecast

$-5B $-1B $3B $7B $11B $15B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$15.20M$10.29B$9.43B$930.30M-----
Avg Forecast$-384.83M$8.76B$8.49B$1.06B$-418.00M$-827.47M$-822.38M$-750.84M$-595.90M
High Forecast$-254.87M$11.73B$11.26B$1.17B$-315.60M$-13.70M$-80.17M$180.75M$-385.97M
Low Forecast$-515.07M$5.80B$6.11B$953.15M$-1.10B$-1.59B$-2.05B$-2.23B$-855.45M
Surprise %-103.95%17.46%11.15%-12.31%-----

BNTX Forecast FAQ

Is BioNTech SE stock a buy?

BioNTech SE stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BioNTech SE is a favorable investment for most analysts.

What is BioNTech SE's price target?

BioNTech SE's price target, set by 23 Wall Street analysts, averages $118.67 over the next 12 months. The price target range spans from $110 at the low end to $134 at the high end, suggesting a potential 13.11% change from the previous closing price of $104.92.

How does BioNTech SE stock forecast compare to its benchmarks?

BioNTech SE's stock forecast shows a 13.11% upside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for BioNTech SE over the past three months?

  • June 2025: 17.39% Strong Buy, 60.87% Buy, 21.74% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 14.29% Strong Buy, 61.90% Buy, 23.81% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 22.73% Strong Buy, 59.09% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.

What is BioNTech SE’s EPS forecast?

BioNTech SE's average annual EPS forecast for its fiscal year ending in December 2024 is $-3.16, marking a 0% decrease from the reported $0 in 2023. Estimates for the following years are $-3.35 in 2025, $-3.47 in 2026, $-3.25 in 2027, and $-2.46 in 2028.

What is BioNTech SE’s revenue forecast?

BioNTech SE's average annual revenue forecast for its fiscal year ending in December 2024 is $2.74B, reflecting a -28.21% decrease from the reported $3.82B in 2023. The forecast for 2025 is $2.67B, followed by $2.67B for 2026, $2.88B for 2027, and $3.64B for 2028.

What is BioNTech SE’s net income forecast?

BioNTech SE's net income forecast for the fiscal year ending in December 2024 stands at $-418M, representing a -144.93% decrease from the reported $930.3M in 2023. Projections indicate $-827M in 2025, $-822M in 2026, $-751M in 2027, and $-596M in 2028.